Faisal Khurshid
Stock Analyst at Leerink Partners
(0.28)
# 2668
Out of 5,370 analysts
20
Total ratings
46.15%
Success rate
-8.56%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IRWD Ironwood Pharmaceuti... | Maintains: Market Perform | 3 1 | 0.68 | 47.06% | 2 | Apr 14, 2025 | |
SYRE Spyre Therapeutics | Initiates Coverage On: Outperform | 45 | 17.23 | 161.17% | 1 | Apr 8, 2025 | |
NRIX Nurix Therapeutics | Initiates Coverage On: Market Perform | 16 | 11.87 | 34.79% | 1 | Mar 17, 2025 | |
STTK Shattuck Labs | Initiates Coverage On: Outperform | 4 | 0.99 | 304.04% | 1 | Mar 17, 2025 | |
PLRX Pliant Therapeutics | Downgrades: Market Perform | 33 2 | 1.34 | 49.25% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 16 | 5.46 | 193.04% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 60 60 | 46.85 | 28.07% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 80 | 64.33 | 24.36% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 15 | 1.2 | 1150% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 7 | 6.35 | 10.24% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 45 | 19.25 | 133.77% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 24 | 28.82 | -16.72% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 7 | 1.54 | 354.55% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 8 | 3.81 | 109.97% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 5 | 0.82 | 509.76% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 17 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 11 | 3.27 | 236.39% | 1 | Mar 21, 2023 |